| 57.07 -4.93 (-7.95%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 72.56 |
1-year : | 78.23 |
| Resists | First : | 62.12 |
Second : | 66.98 |
| Pivot price | 57.64 |
|||
| Supports | First : | 54.27 |
Second : | 45.15 |
| MAs | MA(5) : | 60 |
MA(20) : | 58.27 |
| MA(100) : | 58.6 |
MA(250) : | 49.35 |
|
| MACD | MACD : | 0 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 66.7 |
D(3) : | 74.3 |
| RSI | RSI(14): 45.5 |
|||
| 52-week | High : | 66.98 | Low : | 32.26 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BRKR ] has closed above bottom band by 43.6%. Bollinger Bands are 14.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 60.23 - 60.56 | 60.56 - 60.83 |
| Low: | 55.24 - 55.63 | 55.63 - 55.96 |
| Close: | 56.47 - 57.08 | 57.08 - 57.58 |
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Fri, 30 Oct 2026
Bruker Drops 9.5% Amid Sector-Wide Selling - AlphaStreet
Fri, 30 Oct 2026
309,800 Shares of Bruker Corporation $BRKR Acquired by Brooklands Fund Management Ltd - MarketBeat
Wed, 28 Oct 2026
Bruker Corporation (NASDAQ: BRKR) Rises 4.31% to USD 60.74 With Deepening Loss and Neutral Oscillators - Kalkine India
Wed, 28 Oct 2026
Bruker Corporation (BRKR) Stock Forecasts - Yahoo Finance
Tue, 20 Oct 2026
Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast - Business Wire
Sun, 18 Oct 2026
Bruker Corporation $BRKR Stock Holdings Decreased by Curated Wealth Partners LLC - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 152 (M) |
| Shares Float | 104 (M) |
| Held by Insiders | 26.9 (%) |
| Held by Institutions | 95.5 (%) |
| Shares Short | 12,410 (K) |
| Shares Short P.Month | 12,010 (K) |
| EPS | -0.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.63 |
| Profit Margin | -2.1 % |
| Operating Margin | 9.8 % |
| Return on Assets (ttm) | 3.1 % |
| Return on Equity (ttm) | -3 % |
| Qtrly Rev. Growth | 5.1 % |
| Gross Profit (p.s.) | 11.15 |
| Sales Per Share | 22.97 |
| EBITDA (p.s.) | 3.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 190 (M) |
| Levered Free Cash Flow | 180 (M) |
| PE Ratio | -81.53 |
| PEG Ratio | 1.5 |
| Price to Book value | 3.65 |
| Price to Sales | 2.48 |
| Price to Cash Flow | 45.66 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|